Xeris Biopharma Holdings (XERS) Net Cash Flow Growth (1y) (2021 - 2026)
Xeris Biopharma Holdings (XERS) Net Cash Flow Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.91 Bn | 88.04 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.91 Bn | 32.17 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.05 Bn | 20.89 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.82 Bn | 16.50 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -1,020.00% |
| 10 | Xeris Biopharma Holdings | 1.42 Bn | 1.31 Bn | 72.55 Mn | 105.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 105.37% |
| Dec 31, 2025 | 56.95% |
| Sep 30, 2025 | 2,010.81% |
| Jun 30, 2025 | 116.61% |
| Mar 31, 2025 | -176.97% |
| Dec 31, 2024 | -41.30% |
| Sep 30, 2024 | 5,751.85% |
| Jun 30, 2024 | -7.39% |
| Mar 31, 2024 | 93.30% |
| Dec 31, 2023 | -49.99% |
| Sep 30, 2023 | 99.76% |
| Jun 30, 2023 | 43.83% |
| Mar 31, 2023 | -294.47% |
| Dec 31, 2022 | 442.41% |
| Sep 30, 2022 | -173.62% |
| Jun 30, 2022 | -180.47% |
| Mar 31, 2022 | 25.84% |
| Dec 31, 2021 | 2,746.60% |